These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 24478318)

  • 1. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
    Ou SH; Jänne PA; Bartlett CH; Tang Y; Kim DW; Otterson GA; Crinò L; Selaru P; Cohen DP; Clark JW; Riely GJ
    Ann Oncol; 2014 Feb; 25(2):415-22. PubMed ID: 24478318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer.
    Hong X; Chen Q; Ding L; Liang Y; Zhou N; Fang W; Chen X; Wu H
    Oncotarget; 2017 Jun; 8(25):41631-41640. PubMed ID: 28427213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
    Shaw AT; Yeap BY; Solomon BJ; Riely GJ; Gainor J; Engelman JA; Shapiro GI; Costa DB; Ou SH; Butaney M; Salgia R; Maki RG; Varella-Garcia M; Doebele RC; Bang YJ; Kulig K; Selaru P; Tang Y; Wilner KD; Kwak EL; Clark JW; Iafrate AJ; Camidge DR
    Lancet Oncol; 2011 Oct; 12(11):1004-12. PubMed ID: 21933749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
    Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
    Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study.
    Yang G; Ma D; Xu H; Yang L; Li J; Xing P; Hao X; Wang Y
    Cancer Med; 2019 Oct; 8(13):5823-5830. PubMed ID: 31407528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
    Cui S; Zhao Y; Dong L; Gu A; Xiong L; Qian J; Zhang W; Niu Y; Pan F; Jiang L
    Cancer Med; 2016 Jun; 5(6):1013-21. PubMed ID: 26880708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
    Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G
    J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
    N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.
    Xing P; Wang S; Wang Q; Ma D; Hao X; Wang M; Wang Y; Shan L; Xin T; Liang L; Liang H; Du Y; Zhang Z; Li J
    Target Oncol; 2019 Jun; 14(3):325-333. PubMed ID: 31025247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.
    Yoshida T; Oya Y; Tanaka K; Shimizu J; Horio Y; Kuroda H; Sakao Y; Hida T; Yatabe Y
    Lung Cancer; 2016 Jul; 97():43-7. PubMed ID: 27237026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
    Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
    Solomon BJ; Mok T; Kim DW; Wu YL; Nakagawa K; Mekhail T; Felip E; Cappuzzo F; Paolini J; Usari T; Iyer S; Reisman A; Wilner KD; Tursi J; Blackhall F;
    N Engl J Med; 2014 Dec; 371(23):2167-77. PubMed ID: 25470694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
    Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
    Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
    Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
    Camidge DR; Bang YJ; Kwak EL; Iafrate AJ; Varella-Garcia M; Fox SB; Riely GJ; Solomon B; Ou SH; Kim DW; Salgia R; Fidias P; Engelman JA; Gandhi L; Jänne PA; Costa DB; Shapiro GI; Lorusso P; Ruffner K; Stephenson P; Tang Y; Wilner K; Clark JW; Shaw AT
    Lancet Oncol; 2012 Oct; 13(10):1011-9. PubMed ID: 22954507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.